Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b/2 study of IM-101 in generalized and ocular myasthenia gravis
2025-522406-20-00Phase 2Authorised
- Sponsor
- ImmunAbs
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in myasthenia gravis (MG) comparing IM-101 with Placebo (2 arms). Planned start Jun 2026; status: authorised.
02
Drugs
IM-101
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2025-522406-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522406-20-00.